Questo sito non supporta Internet Explorer. E’ consigliato utilizzare un browser differente (per esempio Edge, Chrome, Firefox, Safari o simili) per avere una migliore esperienza di navigazione.

¶ pazienti naїve all'insulina (senza pregressa esposizione insulinica)

* Time in range (TIR): misurazione clinica che deriva dai dati di CGM

§ dTIR: derived time in range (calcolato utilizzando le misurazioni SMBG-dTIR a 9 punti).

# come da raccomandazioni.

 

 

Bibliografia

1. Philis-Tsimikas A et al. Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 Diabetes. J Diabetes Sci Technol. 2023 Jan 29;19322968221149041. doi: 10.1177/19322968221149041.

2. Annali AMD 2022. Diabete di tipo 2. https://aemmedi.it/wp content/uploads/2023/05/Annali_2022_diabete2-prot.pdf.

3. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019; 42:1593-1603. 

4. Dunn TC, Hayter GA, Doniger KJ, et al. Development of the Likelihood of Low Glucose (LLG) algorithm for evaluating risk of hypoglycemia: a new approach for using continuous glucose data to guide therapeutic decision making. Journal of diabetes science and technology. 2014;8(4):720–730.

5. Ikeda M, Shimazawa R. Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus. J Gen Fam Med. 2019;20(4):129-138.

6. Danne T, Nimri R, Battelino T, et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631-1640.

7. Lu J, Ma X, Zhou J, et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes. Diabetes Care. 2018; 41(11):2370-2376.

8. Mayeda L, Katz R, Ahmad I, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Research and Care 2020; 8(1):e000991.

9. Ranjan AG, Rosenlund SV, Hansen TW, et al. Improved Time in Range Over 1 Year Is Associated With Reduced Albuminuria in Individuals With Sensor Augmented Insulin Pump-Treated Type 1 Diabetes. Diabetes Care. 2020; 43(11):2882-2885.

10. Lu J, Ma X, Shen Y, et al. Time in Range Is Associated with Carotid Intima-Media Thickness in Type 2 Diabetes. Diabetes Technol Ther. 2020; 22(2):72-78.

11. Lu J, Wang C, Shen Y, et al. Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study. Diabetes Care. 2021; 44(2):549-555.

12. diMeglio LA, Kanapka, LG, DeSalvo, DJ, Anderson BJ, et al. Time spent outside of target glucose range for young children with type 1 diabetes: a continuous glucose monitor study. Diabet Med. 2020; 37(8):1308–1315.

13. Sandig D, Grimsmann J, Reinauer C, et al. Continuous Glucose Monitoring in Adults with Type 1 Diabetes: Real-World Data from the German/Austrian Prospective Diabetes Follow-Up Registry. Diabetes Technol Ther. 2020; 22(8):602-612.

14. Tansey M, Beck R, Ruedy K, et al. Persistently high glucose levels in young children with type 1 diabetes. Pediatr Diabetes. 2016; 17(2):93-100.

15. Ling J, Poon EWM, Yang A, et al. Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin naïve Chinese Type 2 Diabetes Patients. Diabetes Ther. 2021; 12(5):1399-1413.

16. Rodrigues R, Rossi ICB, Rossi BF, et al. New glycemic metrics and traditional clinical and laboratory profiles of children and adolescents with type 1 diabetes mellitus in an outpatient follow-up. Diabetes Res Clin Pract. 2021;173:108680. Epub ahead of print. DOI: 10.1016/j.diabres.2021.108680.

17. Furler J, O’Neal D, Speight J, et al. Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial. Lancet Diabetes Endocrinol. 2020; 8(1):17-26.

 

 

Xultophy® AIC n. 043619030 - Classe A - Prezzo al pubblico 370,98 €. Medicinale soggetto a prescrizione medica (RR).

 

Materiale promozionale depositato presso AIFA in data 12/01/2024 - Codice deposito aziendale IT23XUM00044

 

Novo Nordisk e Xultophy® sono marchi registrati di proprietà della Novo Nordisk A/S Danimarca.

 

Materiale destinato unicamente agli operatori sanitari. Vietata la distribuzione o l’esposizione al pubblico.

 

Per il Riassunto delle Caratteristiche di Prodotto di Xultophy® clicca qui